Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 27 | 2024 | 5820 | 2.410 |
Why?
|
Carcinoma, Squamous Cell | 10 | 2024 | 4022 | 1.980 |
Why?
|
Carcinoma, Basal Cell | 5 | 2024 | 560 | 1.520 |
Why?
|
Carcinoma, Merkel Cell | 9 | 2024 | 328 | 1.400 |
Why?
|
Immunotherapy | 19 | 2024 | 4649 | 1.320 |
Why?
|
Melanoma | 14 | 2024 | 5706 | 1.250 |
Why?
|
Oncolytic Viruses | 3 | 2022 | 344 | 0.800 |
Why?
|
Prodrugs | 1 | 2022 | 261 | 0.700 |
Why?
|
Neoadjuvant Therapy | 1 | 2024 | 2823 | 0.420 |
Why?
|
Riluzole | 3 | 2023 | 59 | 0.410 |
Why?
|
Kidney Transplantation | 2 | 2024 | 4236 | 0.370 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3161 | 0.340 |
Why?
|
Oncolytic Virotherapy | 4 | 2023 | 516 | 0.320 |
Why?
|
Neoplasms | 11 | 2024 | 22158 | 0.320 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4246 | 0.300 |
Why?
|
Microsatellite Instability | 2 | 2021 | 715 | 0.270 |
Why?
|
Antineoplastic Agents | 6 | 2023 | 13635 | 0.240 |
Why?
|
Injections, Intralesional | 3 | 2020 | 277 | 0.240 |
Why?
|
Cytokines | 1 | 2019 | 7390 | 0.220 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1875 | 0.210 |
Why?
|
Goats | 1 | 2022 | 167 | 0.210 |
Why?
|
Radiosurgery | 3 | 2016 | 1342 | 0.190 |
Why?
|
Glutamates | 1 | 2022 | 389 | 0.180 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2023 | 237 | 0.180 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9180 | 0.180 |
Why?
|
Humans | 51 | 2024 | 761326 | 0.170 |
Why?
|
Neoplasm, Residual | 1 | 2024 | 1008 | 0.160 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2020 | 361 | 0.160 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58946 | 0.150 |
Why?
|
Retrospective Studies | 15 | 2024 | 80575 | 0.150 |
Why?
|
Disease Progression | 4 | 2024 | 13500 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2024 | 9275 | 0.140 |
Why?
|
Receptors, Dopamine D2 | 1 | 2019 | 485 | 0.140 |
Why?
|
Receptors, Metabotropic Glutamate | 1 | 2018 | 195 | 0.130 |
Why?
|
Ultraviolet Rays | 1 | 2021 | 1079 | 0.130 |
Why?
|
Tumor Microenvironment | 4 | 2022 | 3873 | 0.130 |
Why?
|
Guidelines as Topic | 1 | 2022 | 1385 | 0.130 |
Why?
|
Brain Neoplasms | 2 | 2015 | 9030 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 11735 | 0.120 |
Why?
|
Medicare Part D | 1 | 2020 | 355 | 0.120 |
Why?
|
Interferons | 1 | 2018 | 705 | 0.120 |
Why?
|
Bayes Theorem | 1 | 2022 | 2329 | 0.110 |
Why?
|
Combined Modality Therapy | 4 | 2023 | 8526 | 0.110 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2023 | 4576 | 0.110 |
Why?
|
Aged | 16 | 2024 | 169179 | 0.110 |
Why?
|
Survival Analysis | 3 | 2020 | 10075 | 0.110 |
Why?
|
Middle Aged | 17 | 2024 | 220774 | 0.110 |
Why?
|
Cohort Studies | 4 | 2024 | 41440 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2859 | 0.100 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1409 | 0.100 |
Why?
|
Antibodies, Viral | 1 | 2024 | 3155 | 0.100 |
Why?
|
Cranial Irradiation | 1 | 2015 | 390 | 0.100 |
Why?
|
Prescription Drugs | 1 | 2020 | 631 | 0.100 |
Why?
|
Influenza Vaccines | 1 | 2019 | 767 | 0.100 |
Why?
|
Prognosis | 6 | 2024 | 29588 | 0.100 |
Why?
|
Interleukin-2 | 1 | 2019 | 1891 | 0.100 |
Why?
|
Enzyme Inhibitors | 1 | 2022 | 3710 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 612 | 0.100 |
Why?
|
Biological Products | 1 | 2020 | 913 | 0.090 |
Why?
|
Male | 19 | 2024 | 360621 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1486 | 0.090 |
Why?
|
Craniotomy | 1 | 2015 | 741 | 0.090 |
Why?
|
Down-Regulation | 1 | 2018 | 2913 | 0.090 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2811 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2891 | 0.090 |
Why?
|
Spinal Neoplasms | 1 | 2016 | 716 | 0.090 |
Why?
|
Female | 16 | 2024 | 392485 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 1432 | 0.070 |
Why?
|
Graft Rejection | 1 | 2020 | 4446 | 0.070 |
Why?
|
Health Care Costs | 1 | 2019 | 3243 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2022 | 7999 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7389 | 0.070 |
Why?
|
Comorbidity | 1 | 2020 | 10498 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5363 | 0.060 |
Why?
|
Neoplasm Staging | 3 | 2024 | 11098 | 0.060 |
Why?
|
Adult | 10 | 2024 | 221122 | 0.050 |
Why?
|
Proteins | 1 | 2018 | 6034 | 0.050 |
Why?
|
Philadelphia | 1 | 2023 | 266 | 0.050 |
Why?
|
Treatment Outcome | 5 | 2020 | 64645 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2020 | 1784 | 0.050 |
Why?
|
Lymph Nodes | 2 | 2023 | 3469 | 0.050 |
Why?
|
Polyomavirus Infections | 1 | 2024 | 194 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5303 | 0.050 |
Why?
|
Acetamides | 1 | 2023 | 256 | 0.050 |
Why?
|
Tumor Virus Infections | 1 | 2024 | 438 | 0.050 |
Why?
|
Containment of Biohazards | 1 | 2020 | 37 | 0.050 |
Why?
|
Niacinamide | 1 | 2023 | 413 | 0.050 |
Why?
|
Quality of Life | 1 | 2022 | 13355 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2023 | 883 | 0.040 |
Why?
|
Oximes | 1 | 2022 | 303 | 0.040 |
Why?
|
Squalene | 1 | 2019 | 35 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2023 | 529 | 0.040 |
Why?
|
Animals | 5 | 2023 | 168388 | 0.040 |
Why?
|
Pyrimidinones | 1 | 2022 | 385 | 0.040 |
Why?
|
Basic-Leucine Zipper Transcription Factors | 1 | 2019 | 151 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6473 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 641 | 0.040 |
Why?
|
Societies, Medical | 2 | 2024 | 3905 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2020 | 384 | 0.040 |
Why?
|
United States | 3 | 2021 | 72317 | 0.040 |
Why?
|
Skin | 2 | 2023 | 4482 | 0.040 |
Why?
|
Hydroxychloroquine | 1 | 2022 | 426 | 0.040 |
Why?
|
Interleukin-15 | 1 | 2018 | 185 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2018 | 397 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 857 | 0.030 |
Why?
|
Pyridones | 1 | 2022 | 808 | 0.030 |
Why?
|
Lymphatic Metastasis | 1 | 2024 | 2914 | 0.030 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2019 | 445 | 0.030 |
Why?
|
Imidazoles | 1 | 2022 | 1179 | 0.030 |
Why?
|
Prednisone | 1 | 2020 | 1564 | 0.030 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 753 | 0.030 |
Why?
|
Drugs, Generic | 1 | 2020 | 448 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1175 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2019 | 1036 | 0.030 |
Why?
|
Autophagy | 1 | 2022 | 1321 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2019 | 1560 | 0.030 |
Why?
|
Seasons | 1 | 2019 | 1519 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 300 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4908 | 0.030 |
Why?
|
Pyrazoles | 1 | 2023 | 2007 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1079 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2022 | 2052 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1089 | 0.020 |
Why?
|
Drug Costs | 1 | 2020 | 1183 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4013 | 0.020 |
Why?
|
Mice | 3 | 2023 | 81474 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3734 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2203 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2024 | 12972 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2016 | 946 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2019 | 2985 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2018 | 6525 | 0.020 |
Why?
|
Influenza, Human | 1 | 2019 | 1521 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4321 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13333 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3381 | 0.020 |
Why?
|
Health Expenditures | 1 | 2020 | 2365 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2023 | 5665 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2023 | 16966 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2019 | 4764 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54405 | 0.020 |
Why?
|
Time Factors | 2 | 2019 | 39974 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3687 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2015 | 6815 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5297 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2023 | 18234 | 0.010 |
Why?
|
Patient Selection | 1 | 2016 | 4244 | 0.010 |
Why?
|
Risk Factors | 2 | 2023 | 74152 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6758 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 22154 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9994 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10203 | 0.010 |
Why?
|
Inflammation | 1 | 2018 | 10760 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26108 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 30044 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23427 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 59196 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 88305 | 0.010 |
Why?
|
Concepts
(158)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(53)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_